Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · INNOVACAP

INNOVACAP

HealthcarePharmaceuticals & Biotechnology₹6004 cr market cap
₹1005.30 ▼ -4.27% today As of 19 Nov 2026
52-week low ₹644.7552-week high ₹1297.60

-19.1% from the 52-week high · +62.9% above the low

Innova Captab Ltd is a IN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Panchkula, Haryana. The company went IPO on 2023-12-29. Innova Captab Ltd is an integrated pharmaceutical company. The firm is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The company has presence across the pharmaceuticals value chain, including research and development, manufacturing, drug distribution and marketing and exports. Its business includes CDMO business, domestic branded generics business, and international branded generic product business. Its CDMO business provides research, product development and manufacturing services. Its branded generics business consists of the development, manufacture and distribution of generic formulation products, which are marketed and distributed in India under its own brand names through online and offline channels. Its generic drug products are also available online through various e-commerce pharmacy sites. The company has developed a diversified branded generics product portfolio including Tablets, capsules, dry syrups, dry powder injection, ointments and liquid orals.

The short version. INNOVACAP reported revenue of ₹496 crore for Sep 2026, up 30.5% from a year earlier. Net profit was ₹42 crore (up 40.0% year on year). Return on equity was 13.2% in Mar 2026. Promoter holding was 50.9% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

INNOVACAP trades 19.1% below its 52-week high and 62.9% above its 52-week low.

Change over period: —

1M+4.8%
3M+1.0%
6M+19.3%
1Y+42.9%

2 · The business

Is it growing?

Sales, year on year+30.5%

Sep 2026 revenue of ₹496 cr.

Profit, year on year+40.0%

Sep 2026 net profit of ₹42 cr.

Net margin8.5%

0.7 pts higher than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue496471448450380352315316
Net profit4244404230313034
Net margin %8.59.49.09.47.88.89.410.8
EPS (₹)7.417.717.057.375.185.425.175.98

Annual

FY2026FY2025FY2024
Revenue163012441081
Net profit14312894
Net margin %8.810.38.7
EPS (₹)25.0222.4116.49

3 · The quality

How well does it turn capital into profit?

Return on equity was 13.2% in Mar 2026; debt to equity is 0.32.

Profitability · 3 years

Returns and margins

Mar 2026Mar 2025Mar 2024
Return on equity %13.213.411.3
Return on capital %15.314.114.3
EBITDA margin %15.315.815.3
Net margin %8.710.28.6

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
Debt to equity0.32
Interest cover12.1x
Current ratio1.87
P/E ratio38.4

4 · The owners

Who holds it, and are they adding?

Promoter holding50.9%

Unchanged over 8 quarters.

Foreign institutions0.84%

Up 0.1 pts over 8 quarters.

Domestic institutions19.16%

Down 0.8 pts over 8 quarters.

Mutual fund schemes18

+6 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter50.950.950.950.950.950.950.950.90.0
FII0.740.340.230.080.110.230.340.84+0.1
DII19.9619.7619.6720.1720.2420.1419.9219.16-0.8
Public28.4128.9929.228.8528.7628.7328.8429.09+0.68

Mutual fund holdings · Oct 2026

18 schemes hold this stock

12 the month before.

  • CANARA ROBECO MANUFACTURING FUND1.76% of NAV
  • SBI Balanced Hybrid Fund1.42% of NAV
  • SBI Healthcare Opportunities Fund1.41% of NAV
  • Kotak Consumption Fund1.38% of NAV
  • CANARA ROBECO SMALL CAP FUND1.23% of NAV
  • Kotak Healthcare Fund1.19% of NAV
  • CANARA ROBECO VALUE FUND1.19% of NAV
  • Invesco India Manufacturing Fund1.14% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for INNOVACAP are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about INNOVACAP

What is the INNOVACAP share price?

INNOVACAP (INNOVACAP) last closed at ₹1,005.30, down 4.27% on the day. Its 52-week range is ₹644.75 to ₹1,297.60.

What is the market cap of INNOVACAP?

INNOVACAP has a market capitalisation of about ₹6,004 crore. Its price-to-earnings ratio is 38.4.

How are INNOVACAP's latest results?

INNOVACAP reported revenue of ₹496 crore for Sep 2026, up 30.5% from a year earlier. Net profit was ₹42 crore (up 40.0% year on year). Return on equity was 13.2% in Mar 2026. Promoter holding was 50.9% in Sep 2026, up 0.00 points over 8 quarters.

Who owns INNOVACAP?

As of Sep 2026, shareholding was: Promoter 50.9%, FII 0.84%, DII 19.16%, Public 29.09%.

How many mutual funds hold INNOVACAP?

18 mutual fund schemes held INNOVACAP in October 2026. That compares with 12 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 30 Jan 2026 · Interim Dividend - Rs. 2

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.